Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03089268 | Molecular and Histological Characteristics of Serrated Lesions of the Colon(SERRACOLON) | active not recruiting | — | 700 | Hospital Universitario La FeOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT02193503 | MVX-ONCO-1 in Patients With Solid Tumor | active not recruiting | Phase 1 | 34 | Maxivax SAINDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03825796 | CPX-351 Plus Enasidenib for Relapsed AML | active not recruiting | Phase 2 | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05515029 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | active not recruiting | Phase 3 | 56 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05602935 | Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study | active not recruiting | Phase 2 | 29 | The Second Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05569811 | NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial(VALENTINE) | active not recruiting | Phase 2 | 120 | SOLTI Breast Cancer Research GroupOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04611997 | IGG Using in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy | active not recruiting | Phase 3 | 240 | Fujian Medical UniversityOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06041061 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years | active not recruiting | Phase 3 | 18,000 | Sinocelltech Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT03501381 | High Dose IL 2 and Entinostat in RCC | active not recruiting | Phase 2 | 46 | Roberto PiliOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT00003861 | Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia | active not recruiting | — | 840 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT04613557 | Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma(IMMUNICY-1) | active not recruiting | Phase 1 | 18 | Celyad Oncology SAINDUSTRY | 2 | Aug 31, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT00898456 | Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia | active not recruiting | — | 600 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04592393 | Pancreas Cancer Surveillance Using an Abbreviated MRI | active not recruiting | N/A | 200 | Seoul National University HospitalOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05433701 | Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC | active not recruiting | N/A | 178 | Jonggi ChoiOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT03044977 | Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors | active not recruiting | Early Phase 1 | 20 | David BushnellOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05969691 | Radiomics-Based Visualization and Quantitative Validation of IDH1 Heterogeneity in Gliomas | active not recruiting | N/A | 18 | Mingge LLCINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT04645706 | Innate T Cells and TKI Discontinuation(TIBIOP-LMC) | active not recruiting | — | 92 | Poitiers University HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00909909 | Radiation Therapy in Treating Women With Early Stage Breast Cancer | active not recruiting | Phase 2 | 200 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04764227 | Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) | active not recruiting | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04223102 | Microbiome and Rectal Cancer | active not recruiting | N/A | 40 | University of South FloridaOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05955521 | Exosome as the Prognostic and Predictive Biomarker in EBC Patients | active not recruiting | N/A | 200 | Samsung Medical CenterOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT02665065 | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia(SIERRA) | active not recruiting | Phase 3 | 153 | Actinium PharmaceuticalsINDUSTRY | 2 | Jul 19, 2023 | clinicaltrials |
| NCT05951127 | Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC(LEO) | active not recruiting | N/A | 141 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT01357772 | Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up(TAM-01) | active not recruiting | Phase 3 | 500 | Andrea DeCensiOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05824325 | Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY） | active not recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT03347162 | Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer | active not recruiting | — | 1,000 | Rigshospitalet, DenmarkOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05873361 | Postoperative Follow-up of Asymptomatic Papillary Microcarcinomas on Patient Survival(MIPTHYS) | active not recruiting | — | 500 | University Hospital, ToulouseOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05904327 | Circulating Biomarkers in Oropharyngeal Cancers(CIRCOS) | active not recruiting | — | 130 | Region Örebro CountyOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04642508 | The PreQ-20 TRIAL, a Prospective Cohort Study of Patients Undergoing Prepectoral Breast Reconstruction(PreQ-20) | active not recruiting | N/A | 81 | University Hospital A CoruñaOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT02889458 | Hong Kong Breast Cancer Study | active not recruiting | — | 7,000 | The University of Hong KongOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03306121 | TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 322 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03488667 | Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma | active not recruiting | Phase 2 | 40 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT03948035 | Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | active not recruiting | Phase 3 | 576 | Wuerzburg University HospitalOTHER | 2 | May 6, 2023 | clinicaltrials |
| NCT02881242 | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT03381105 | From PSA to Stockholm3: Study Part 1(PSA2STHLM3/1) | active not recruiting | — | 13,431 | Helse Stavanger HFOTHER_GOV | 1 | Apr 24, 2023 | clinicaltrials |
| NCT04526834 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma(CERTAIN) | active not recruiting | Phase 1 | 21 | Tessa TherapeuticsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT00268476 | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy(STAMPEDE) | active not recruiting | Phase 2 / Phase 3 | 11,992 | Medical Research CouncilOTHER_GOV | 2 | Apr 18, 2023 | clinicaltrials |
| NCT04928222 | Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II) | active not recruiting | Phase 1 / Phase 2 | 25 | SkinJect, Inc.INDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05811169 | Quest for Tumour Evolution of Non-small Cell Lung Cancer | active not recruiting | — | 60 | The University of Hong KongOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04268706 | Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) | active not recruiting | Phase 2 | 97 | Tessa TherapeuticsINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04138914 | Phase II Trial of Focal Cryotherapy for Prostate Cancer | active not recruiting | N/A | 30 | Singapore General HospitalOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05352828 | Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy(ACTION) | active not recruiting | Phase 1 | 15 | Tessa TherapeuticsINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT02315196 | Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | active not recruiting | Phase 2 | 62 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03064087 | Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples(VALHUDES) | active not recruiting | — | 500 | Marc ArbynOTHER_GOV | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03688451 | Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma | active not recruiting | Phase 2 | 20 | Tahir LatifOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT02068196 | A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.(Ipi4) | active not recruiting | Phase 4 | 150 | Oslo University HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05784142 | Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)(CHIC) | active not recruiting | Phase 2 | 55 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03544736 | Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) | active not recruiting | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05656053 | Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging | active not recruiting | — | 30 | Mingge LLCINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 2, 2023source: clinicaltrials